PURPOSE: To show whether single nucleotide polymorphisms (SNP) of drug metabolic genes were associated with toxicity of 2',2'-difluoro 2'-deoxycytidine (gemcitabine)-based chemoradiotherapy and overall survival (OS) of patients with pancreatic cancer. EXPERIMENTAL DESIGN: We evaluated 17 SNPs of the CDA, dCK, DCTD, RRM1, hCNT1, hCNT2, hCNT3, and hENT1 genes in 154 patients with potentially resectable pancreatic adenocarcinoma who were enrolled in clinical trials at The University of Texas M.D. Anderson Cancer Center (Houston, TX) from February 1999 to January 2006, with follow-up until April 2009. Patients received neoadjuvant concurrent gemcitabine and radiation therapy with or without gemcitabine-cisplatin induction therapy. The association of genotypes with toxicity or OS was tested, respectively, by logistic regression and Cox regression analysis. RESULTS: None of the 17 SNPs, individually, had a significant association with OS. A combined genotype effect of CDA A-76C, dCK C-1205T, DCTD T-47C, hCNT3 C-69T, hENT1 T-549C, and hENT1 C913T on OS was observed. Patients carrying 0 to 1 (n = 43), 2 to 3 (n = 77), or 4 to 6 (n = 30) variant alleles had median survival time of 31.5, 21.4, and 17.5 months, respectively. The hazard ratio of dying was 1.71 (95% confidence interval, 1.06-2.76) and 3.16 (95% confidence interval, 1.77-5.63) for patients carrying two to three or four to six at-risk genotypes (P = 0.028 and P < 0.001), respectively, after adjusting for clinical predictors. CDA C111T, dCK C-1205T, dCK A9846G, and hCNT3 A25G, individually and jointly, had a significant association with neutropenia toxicity. CONCLUSIONS: These observations suggest that polymorphic variations of drug metabolic genes were associated with toxicity of gemcitabine-based therapy and OS of patients with resectable pancreatic cancer.
PURPOSE: To show whether single nucleotide polymorphisms (SNP) of drug metabolic genes were associated with toxicity of 2',2'-difluoro 2'-deoxycytidine (gemcitabine)-based chemoradiotherapy and overall survival (OS) of patients with pancreatic cancer. EXPERIMENTAL DESIGN: We evaluated 17 SNPs of the CDA, dCK, DCTD, RRM1, hCNT1, hCNT2, hCNT3, and hENT1 genes in 154 patients with potentially resectable pancreatic adenocarcinoma who were enrolled in clinical trials at The University of Texas M.D. Anderson Cancer Center (Houston, TX) from February 1999 to January 2006, with follow-up until April 2009. Patients received neoadjuvant concurrent gemcitabine and radiation therapy with or without gemcitabine-cisplatin induction therapy. The association of genotypes with toxicity or OS was tested, respectively, by logistic regression and Cox regression analysis. RESULTS: None of the 17 SNPs, individually, had a significant association with OS. A combined genotype effect of CDAA-76C, dCKC-1205T, DCTDT-47C, hCNT3C-69T, hENT1 T-549C, and hENT1 C913T on OS was observed. Patients carrying 0 to 1 (n = 43), 2 to 3 (n = 77), or 4 to 6 (n = 30) variant alleles had median survival time of 31.5, 21.4, and 17.5 months, respectively. The hazard ratio of dying was 1.71 (95% confidence interval, 1.06-2.76) and 3.16 (95% confidence interval, 1.77-5.63) for patients carrying two to three or four to six at-risk genotypes (P = 0.028 and P < 0.001), respectively, after adjusting for clinical predictors. CDA C111T, dCKC-1205T, dCKA9846G, and hCNT3 A25G, individually and jointly, had a significant association with neutropenia toxicity. CONCLUSIONS: These observations suggest that polymorphic variations of drug metabolic genes were associated with toxicity of gemcitabine-based therapy and OS of patients with resectable pancreatic cancer.
Authors: C H Baker; J Banzon; J M Bollinger; J Stubbe; V Samano; M J Robins; B Lippert; E Jarvi; R Resvick Journal: J Med Chem Date: 1991-06 Impact factor: 7.446
Authors: Judith R Kroep; Willem J P Loves; Clasina L van der Wilt; Enrique Alvarez; Iannis Talianidis; Epie Boven; Boudewijn J M Braakhuis; Cornelis J van Groeningen; Herbert M Pinedo; Godefridus J Peters Journal: Mol Cancer Ther Date: 2002-04 Impact factor: 6.261
Authors: Jennifer Spratlin; Randeep Sangha; Darryl Glubrecht; Laith Dabbagh; James D Young; Charles Dumontet; Carol Cass; Raymond Lai; John R Mackey Journal: Clin Cancer Res Date: 2004-10-15 Impact factor: 12.531
Authors: Douglas H Osato; Conrad C Huang; Michiko Kawamoto; Susan J Johns; Doug Stryke; Joanne Wang; Thomas E Ferrin; Ira Herskowitz; Kathleen M Giacomini Journal: Pharmacogenetics Date: 2003-05
Authors: Carlos María Galmarini; Marilyn L Clarke; Lars Jordheim; Cheryl L Santos; Emeline Cros; John R Mackey; Charles Dumontet Journal: BMC Pharmacol Date: 2004-05-24
Authors: Jason A Willis; Sara H Olson; Irene Orlow; Semanti Mukherjee; Robert R McWilliams; Robert C Kurtz; Robert J Klein Journal: Clin Cancer Res Date: 2012-06-04 Impact factor: 12.531
Authors: Hongmei Zeng; Herbert Yu; Lingeng Lu; Dhanpat Jain; Mark S Kidd; M Wasif Saif; Stephen J Chanock; Patricia Hartge; Harvey A Risch Journal: Pancreas Date: 2011-07 Impact factor: 3.327